The aim of the study was to evaluate the activity of decitabine, our preliminary experience with decitabine in patients with a hypomethylating agent, in the treatment of patients with accelerated and blastic phases of CML. 
Introduction
Patients with CML in accelerated or blastic phases were treated with decitabine 100 mg/m 2 over 6 h every 12 h for 5 Decitabine is a potent hypomethylating agent which has days (1000 mg/m 2 /course). Because of prolonged myeloadditional interesting properties including differentiation, in suppression, the dose schedule was subsequently reduced to vitro antileukemic efficacy, and synergism with biologic 75 mg/m 2 over 6 h every 12 h for 5 days (750 mg/m 2 /course). agents such as interferons and retinoids. 1 Hypermethylation of This was decided simultaneously for both accelerated and DNA is one mechanism of tumor progression, and has been blastic phases. However, more patients with accelerated noted in 85 to 100% of patients with acute myelogenous leuphase were entered on study recently. Patients in chronic kemia (AML) and in 50% of those with chronic myelogenous phase CML have been treated on study with a lower dose leukemia (CML). 2 schedule of decitabine, and will be reported separately Previous studies with decitabine in AML salvage have dembecause of limited experience and different therapeutic endonstrated encouraging results. Response rates of 5 to 40% points. Patients with clonal evolution as the only criterion of were reported with decitabine when used as a single agent, accelerated phase will also be reported as part of the chronic and of 30 to 60% when it was used in combination with topophase analysis, since response in accelerated or blastic phase isomerase II reactive agents such as amsacrine or anthracydoes not require suppression of clonal evolution (see below). clines. [3] [4] [5] In myelodysplastic syndrome (MDS) and chronic myelomonocyte leukemia, lower dose schedules of decitabine therapy have also resulted in response rates of 20 to 40%.
Response criteria and statistical methods
This positive experience from Europe with decitabine in leukemia and MDS stimulated interest in studies of the agent Response criteria were as previously described. 6,8,10 A comin myeloid leukemias in the USA. In this analysis, we report plete hematologic response (CHR) required 5% or less marrow blasts with normal peripheral counts and differential, a granulocyte count у10 3 /l, a total WBC count Ͻ10 × 10 3 /l, and a platelet counts у100 × 10 3 lasting for at least 4 weeks. aplastic death and resistant disease criteria were as pre-
viously reported.
10 Table 3 Response in 17 patients with accelerated phase CML
Results

Response No. (percent)
Thirty-seven patients have been entered on study, including 36 with Philadelphia chromosome (Ph)-positive CML and one all had Ph-positive disease. Seventeen had accelerated phase CML; 16 were Ph-positive and one was Ph-negative. Accelerated phase disease was based on the presence of blasts у15% in two patients; blasts + promyelocytes у30% positive metaphases); the other three patients achieved marrow CR, but the platelet counts remained below 100 × 10 3 /l. in two patients; basophils у20% in one patient; platelets Ͻ100 × 10 3 /l in two patients; and multiple features in 10 The highest platelet counts in these three patients were 36, 11, and 90 × 10 3 /l, respectively, prior to loss of response. patients (blastosis and basophilia, two patients; blastosis or basophilia plus thrombocytopenia, two patients; three or more One patient did not return for response evaluation (unknown response, Table 2 ). accelerated features, six patients).
In accelerated phase CML, nine patients (51%) achieve objective response, including six (35%) who returned to a second chronic phase disease, two of them achieving a cytoResponse genetic response (Ph suppression to 15 and 66% Ph-positive metaphases, respectively). In the two patients in PHR, the perThe response data are summarized in Tables 2 and 3 . In blastic phase CML, five patients achieved objective responses cent of peripheral blasts was always less than 5% as their response lasted. The patient with hematologic improvement (25%) including two patients (10%) with CHR, one of them with partial cytogenetic response (Ph suppression to 25% Ph-(marrow CR) had a highest platelet count of 25 × 10 3 /l.
There was no significant difference in the incidence of Subsequent courses should not be given unless there is clear evidence of progression (not only persistence of leukemic response by the dose schedule of decitabine (Table 4 ). The median response duration was 17 weeks in blastic phase and cells). This particular pattern of slow clearance of peripheral and 39 weeks in accelerated phase. The median survival was 20 weeks in blastic phase with a 1-year survival rate of 10%. In marrow blastosis and later delayed and prolonged myelosuppression was also noted in previous studies, 1, 11 and raises accelerated phase, the median survival was 58 weeks with a 2-year survival rate of 28%.
important issues regarding (1) the mechanism of action of decitabine; (2) its different antileukemic mechanism from ara-C, hence the potential synergism of the simultaneous or sequential combination once a safe schedule is established;
Side-effects and (3) the timing of subsequent courses of therapy to avoid excessive cumulative myelosuppression and high morbidity Myelosuppression-associated complications were the most significant side-effects, resulting in febrile episodes in 25 and mortality rates. Several recent studies have clarified interesting observations regarding the roles of methylation in CML. patients (68%), including documented infections in 17 patients (46%).
Ben-Yehuda et al 12 demonstrated progressive de novo DNA methylation nested within the BCR-ABL hybrid gene in the An unusual pattern of delayed but prolonged myelosuppression was observed with decitabine. The WBC counts course of CML. Interferon-alpha therapy was associated with reversal to non-methylation state in 13 patients treated, in increased by at least 25% in five of 17 patients (29%) with accelerated phase in the first 5 days. By day 10, five patients contrast to persistence of the methylation state among patients receiving hydroxyurea. 13 Decitabine was also shown to acti-(29%) had WBC counts above 50% of pretreatment levels. By day 15, 11 patients had a WBC count Ͼ1.5 × 10 3 /l. Yet, 15 vate expression of the p16/CDKN2 tumor suppressor gene, 14, 15 which is deficient in a variable percentage of human of the 17 patients (88%) ultimately had a lowest WBC count below 1 × 10 3 /l. leukemias. P16/CDKN2 inhibits the enzyme activity of cyclindependent kinases which mediate phosphorylation of the retiThe median time to granulocyte recovery above 500/l was 48 days (50 days with 1000 mg/m 2 /course vs 45 days with noblastoma gene (RB). High RB phosphorylation has also been associated with poor prognosis in leukemia. 16 Therefore, 750 mg/m 2 /course), and to platelet recovery over 30 × 10 3 /l 31 days (31 days with 1000 mg/m 2 /course vs 25 days with decitabine therapy may interfere with several steps of leukemogenic progression (hypomethylate DNA nested within 750 mg/m 2 /course). These calculations include patients who started with granulocyte counts above 10 3 /l and platelet BCR-ABL gene, enhance p16/CDKN2 tumor suppressor gene expression, suppress activity of cyclin-dependent kinases counts above 50 × 10 3 /l pretreatment. Other side-effects have included mild to moderate nausea mediating Rb phosphorylation, suppress RB phosphorylation) as a means to exert its antileukemic effect. and vomiting (five patients; 12%), diarrhea (seven patients; 17%), and mucositis (three patients; 7%).
Based on these findings, we are currently treating patients with late chronic phase CML resistant to interferon alpha therapy with decitabine at a lower dose schedule (500 mg/m 2 course). The objective of this approach is to induce significant Discussion and sustained cytogenetic responses. If this is observed, then decitabine may be of value as part of an interferon-based In this study, decitabine has shown significant activity in CML transformation. Objective responses were observed in 25% of approach in early chronic phase CML to improve the incidence of major durable cytogenetic responses, which may patients in blastic phase (10% CHR), and in 53% of patients in accelerated phase (35% return to second chronic phase).
further improve prognosis in CML. Based on the significant myelosuppression observed with Prolonged myelosuppression, with its related complications, was the most significant side-effect. Other toxicities decitabine, two programs were proposed in the setting of stem cell rescue therapy. The first program offers decitabine in (gastrointestinal) were mild to moderate, and easily manageable.
combination with busulfan and cyclophosphamide (BUCY-DAC) as part of a preparative regimen for allogeneic stem cell The timing of subsequent courses of decitabine chemotherapy is important. Unlike the common experience with transplantation for poor-risk patients. The improved antileukemic efficacy of the regimen will hopefully reduce the failure conventional chemotherapy, the antileukemic effect with decitabine is slow to occur, and myelosuppression can be rate from leukemia regrowth. The second program proposes to treat patients who relapse post-allogeneic stem cell transdelayed and prolonged. Early control of the disease can be achieved by the addition of a short acting agent (eg hydrea). plantation with decitabine alone followed by allogeneic stem cell rescue. The early updates from both these programs were reported separately. The activity of decitabine in other hematologic disorders (lymphoma, myeloma, chronic lymphocytic leukemia, Wald- 
